7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8 Purity >98.0% (HPLC) Brexpiprazole Intermediate Factory

Short Description:

Name: 7-(4-Chlorobutoxy)quinolin-2(1H)-one

CAS: 913613-82-8

Purity: >98.0% (HPLC)

Appearance: Pale Yellow to Pale Beige Solid

Intermediate of Brexpiprazole (CAS: 913611-97-9)

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

Description:

Ruifu Chemical Supply Brexpiprazole Intermediates
Brexpiprazole CAS 913611-97-9
7-Hydroxyquinolinone CAS 70500-72-0
4-Bromobenzo[b]thiophene CAS 5118-13-8
1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3
7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8
4-Chlorobenzo[b]thiophene CAS 66490-33-3

Chemical Properties:

Chemical Name	7-(4-Chlorobutoxy)quinolin-2(1H)-one
Synonyms	7-(4-Chlorobutoxy)-1H-Quinolin-2-one; Brexpiprazole Impurity 23
CAS Number	913613-82-8
CAT Number	RF-PI1980
Stock Status	In Stock, Production Scale Up to Tons
Molecular Formula	C13H14ClNO2
Molecular Weight	251.71
Boiling Point	460.8±45.0℃
Density	1.216±0.06 g/cm3
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Appearance	Pale Yellow to Pale Beige Solid
Purity / Analysis Method	>98.0% (HPLC)
Infrared Spectrum	Conforms to Structure
NMR	Conforms to Structure
Test Standard	Enterprise Standard
Usage	Intermediate / Impurity of Brexpiprazole (CAS: 913611-97-9)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

FAQ:

Application:

7-(4-Chlorobutoxy)quinolin-2(1H)-one (CAS: 913613-82-8) is an intermediate / impurity of Brexpiprazole (CAS: 913611-97-9). Brexpiprazole is an atypical antipsychotic drug. It is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). The drug received FDA approval on July 13, 2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression. Although Brexpiprazole failed Phase II clinical trials for ADHD, Brexpiprazole has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).